Linee guida SIPMeL per la ricerca dei polimorfismi nella diagnostica di screening della trombofilia

Translated title of the contribution: Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL) Guidelines for laboratory screening DNA testing for thrombophilia

Michele Bertini, Pierfrancesco Agostini, Francesco Bondanini, Maria Matilde Ciriello, Maria Rita Cozzi, Marta Sofia Angela Demicheli, Giovina Di Felice, Cristina Legnani, Giuliana Martini, Cristina Novembrino, Oriana Paoletti, Simona Pedrini, Lucia Ruocco, Agostino Steffan, Lucia Terzuoli, Sophie Testa

Research output: Contribution to journalArticle

Abstract

The term thrombophilia refers to an abnormality of blood coagulation leading to an increased risk of venous thromboembolism and obstetric complications. It may be associated with inherited or acquired risk factors that can be measured in plasma or DNA testing. The utility of laboratory investigation for inherited thrombophilia has been largely debated. Several Guidelines from Scientific Societies and Working Groups are produced in which only deficencies of antithrombin, protein C, protein S and mutations of Factor V Leiden and prothrombin G20210A are established as validated biomarkers at the first-level laboratory screening test for inherited thrombophilia. Nevertheless many others polymorphisms are often proposed as markers to be investigated in a screening set with doubtful clinical benefits, increase of related costs and production of anxiety and fear in the examined people. The Study Group on Coagulation of the Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL) reviewed the medical literature to update the previous edition of SIMeL (Italian Society of Laboratory Medicine) Guidelines for the screening of thrombophilia (2004) and to expand the recommendations about the investigation of the related polymorphisms.

Original languageItalian
Pages (from-to)89-95
Number of pages7
JournalRivista Italiana della Medicina di Laboratorio
Volume13
Issue number2
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Clinical Pathology
Thrombophilia
Pathology
Medicine
Screening
Guidelines
DNA
Testing
Coagulation
Polymorphism
Obstetrics
Antithrombin Proteins
Protein S
Venous Thromboembolism
Prothrombin
Blood Coagulation
Biomarkers
Protein C
Fear
Blood

ASJC Scopus subject areas

  • Medical Laboratory Technology
  • Biochemistry, medical

Cite this

Linee guida SIPMeL per la ricerca dei polimorfismi nella diagnostica di screening della trombofilia. / Bertini, Michele; Agostini, Pierfrancesco; Bondanini, Francesco; Ciriello, Maria Matilde; Cozzi, Maria Rita; Demicheli, Marta Sofia Angela; Di Felice, Giovina; Legnani, Cristina; Martini, Giuliana; Novembrino, Cristina; Paoletti, Oriana; Pedrini, Simona; Ruocco, Lucia; Steffan, Agostino; Terzuoli, Lucia; Testa, Sophie.

In: Rivista Italiana della Medicina di Laboratorio, Vol. 13, No. 2, 01.06.2017, p. 89-95.

Research output: Contribution to journalArticle

Bertini, M, Agostini, P, Bondanini, F, Ciriello, MM, Cozzi, MR, Demicheli, MSA, Di Felice, G, Legnani, C, Martini, G, Novembrino, C, Paoletti, O, Pedrini, S, Ruocco, L, Steffan, A, Terzuoli, L & Testa, S 2017, 'Linee guida SIPMeL per la ricerca dei polimorfismi nella diagnostica di screening della trombofilia', Rivista Italiana della Medicina di Laboratorio, vol. 13, no. 2, pp. 89-95. https://doi.org/10.1007/s13631-017-0148-8
Bertini, Michele ; Agostini, Pierfrancesco ; Bondanini, Francesco ; Ciriello, Maria Matilde ; Cozzi, Maria Rita ; Demicheli, Marta Sofia Angela ; Di Felice, Giovina ; Legnani, Cristina ; Martini, Giuliana ; Novembrino, Cristina ; Paoletti, Oriana ; Pedrini, Simona ; Ruocco, Lucia ; Steffan, Agostino ; Terzuoli, Lucia ; Testa, Sophie. / Linee guida SIPMeL per la ricerca dei polimorfismi nella diagnostica di screening della trombofilia. In: Rivista Italiana della Medicina di Laboratorio. 2017 ; Vol. 13, No. 2. pp. 89-95.
@article{af9113439da044b687016a4ce1848b79,
title = "Linee guida SIPMeL per la ricerca dei polimorfismi nella diagnostica di screening della trombofilia",
abstract = "The term thrombophilia refers to an abnormality of blood coagulation leading to an increased risk of venous thromboembolism and obstetric complications. It may be associated with inherited or acquired risk factors that can be measured in plasma or DNA testing. The utility of laboratory investigation for inherited thrombophilia has been largely debated. Several Guidelines from Scientific Societies and Working Groups are produced in which only deficencies of antithrombin, protein C, protein S and mutations of Factor V Leiden and prothrombin G20210A are established as validated biomarkers at the first-level laboratory screening test for inherited thrombophilia. Nevertheless many others polymorphisms are often proposed as markers to be investigated in a screening set with doubtful clinical benefits, increase of related costs and production of anxiety and fear in the examined people. The Study Group on Coagulation of the Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL) reviewed the medical literature to update the previous edition of SIMeL (Italian Society of Laboratory Medicine) Guidelines for the screening of thrombophilia (2004) and to expand the recommendations about the investigation of the related polymorphisms.",
keywords = "Genetic thrombophilia markers, Guidelines, Laboratory investigation, Polymorphisms, Thrombophilia",
author = "Michele Bertini and Pierfrancesco Agostini and Francesco Bondanini and Ciriello, {Maria Matilde} and Cozzi, {Maria Rita} and Demicheli, {Marta Sofia Angela} and {Di Felice}, Giovina and Cristina Legnani and Giuliana Martini and Cristina Novembrino and Oriana Paoletti and Simona Pedrini and Lucia Ruocco and Agostino Steffan and Lucia Terzuoli and Sophie Testa",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s13631-017-0148-8",
language = "Italian",
volume = "13",
pages = "89--95",
journal = "Rivista Italiana della Medicina di Laboratorio",
issn = "1825-859X",
publisher = "SIMeL Societa Italiana di Medicina di Laboratorio",
number = "2",

}

TY - JOUR

T1 - Linee guida SIPMeL per la ricerca dei polimorfismi nella diagnostica di screening della trombofilia

AU - Bertini, Michele

AU - Agostini, Pierfrancesco

AU - Bondanini, Francesco

AU - Ciriello, Maria Matilde

AU - Cozzi, Maria Rita

AU - Demicheli, Marta Sofia Angela

AU - Di Felice, Giovina

AU - Legnani, Cristina

AU - Martini, Giuliana

AU - Novembrino, Cristina

AU - Paoletti, Oriana

AU - Pedrini, Simona

AU - Ruocco, Lucia

AU - Steffan, Agostino

AU - Terzuoli, Lucia

AU - Testa, Sophie

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The term thrombophilia refers to an abnormality of blood coagulation leading to an increased risk of venous thromboembolism and obstetric complications. It may be associated with inherited or acquired risk factors that can be measured in plasma or DNA testing. The utility of laboratory investigation for inherited thrombophilia has been largely debated. Several Guidelines from Scientific Societies and Working Groups are produced in which only deficencies of antithrombin, protein C, protein S and mutations of Factor V Leiden and prothrombin G20210A are established as validated biomarkers at the first-level laboratory screening test for inherited thrombophilia. Nevertheless many others polymorphisms are often proposed as markers to be investigated in a screening set with doubtful clinical benefits, increase of related costs and production of anxiety and fear in the examined people. The Study Group on Coagulation of the Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL) reviewed the medical literature to update the previous edition of SIMeL (Italian Society of Laboratory Medicine) Guidelines for the screening of thrombophilia (2004) and to expand the recommendations about the investigation of the related polymorphisms.

AB - The term thrombophilia refers to an abnormality of blood coagulation leading to an increased risk of venous thromboembolism and obstetric complications. It may be associated with inherited or acquired risk factors that can be measured in plasma or DNA testing. The utility of laboratory investigation for inherited thrombophilia has been largely debated. Several Guidelines from Scientific Societies and Working Groups are produced in which only deficencies of antithrombin, protein C, protein S and mutations of Factor V Leiden and prothrombin G20210A are established as validated biomarkers at the first-level laboratory screening test for inherited thrombophilia. Nevertheless many others polymorphisms are often proposed as markers to be investigated in a screening set with doubtful clinical benefits, increase of related costs and production of anxiety and fear in the examined people. The Study Group on Coagulation of the Italian Society of Clinical Pathology and Laboratory Medicine (SIPMeL) reviewed the medical literature to update the previous edition of SIMeL (Italian Society of Laboratory Medicine) Guidelines for the screening of thrombophilia (2004) and to expand the recommendations about the investigation of the related polymorphisms.

KW - Genetic thrombophilia markers

KW - Guidelines

KW - Laboratory investigation

KW - Polymorphisms

KW - Thrombophilia

UR - http://www.scopus.com/inward/record.url?scp=85026762112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026762112&partnerID=8YFLogxK

U2 - 10.1007/s13631-017-0148-8

DO - 10.1007/s13631-017-0148-8

M3 - Articolo

AN - SCOPUS:85026762112

VL - 13

SP - 89

EP - 95

JO - Rivista Italiana della Medicina di Laboratorio

JF - Rivista Italiana della Medicina di Laboratorio

SN - 1825-859X

IS - 2

ER -